KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Non-Current Deffered Revenue: 2016-2023

Historic Non-Current Deffered Revenue for Palvella Therapeutics (PVLA) over the last 7 years, with Jun 2023 value amounting to $759,000.

  • Palvella Therapeutics' Non-Current Deffered Revenue fell 96.56% to $759,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $759,000, marking a year-over-year decrease of 96.56%. This contributed to the annual value of $18.7 million for FY2022, which is 51.22% down from last year.
  • According to the latest figures from Q2 2023, Palvella Therapeutics' Non-Current Deffered Revenue is $759,000, which was down 93.53% from $11.7 million recorded in Q1 2023.
  • Palvella Therapeutics' 5-year Non-Current Deffered Revenue high stood at $59.7 million for Q1 2019, and its period low was $759,000 during Q2 2023.
  • In the last 3 years, Palvella Therapeutics' Non-Current Deffered Revenue had a median value of $26.4 million in 2022 and averaged $26.9 million.
  • Per our database at Business Quant, Palvella Therapeutics' Non-Current Deffered Revenue soared by 30.59% in 2021 and then slumped by 96.56% in 2023.
  • Palvella Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $47.3 million in 2019, then declined by 24.03% to $35.9 million in 2020, then rose by 6.97% to $38.4 million in 2021, then slumped by 51.22% to $18.7 million in 2022, then tumbled by 96.56% to $759,000 in 2023.
  • Its Non-Current Deffered Revenue stands at $759,000 for Q2 2023, versus $11.7 million for Q1 2023 and $18.7 million for Q4 2022.